WORCESTER, Mass.--(BUSINESS WIRE)--Biovest International, Inc. (OTCBB: BVTI) announced that a publication in the September 20th issue of the Journal of the National Cancer Institute provides support for its ongoing phase 3 trial of BiovaxID, an autologous immunotherapy for follicular non-Hodgkin’s Lymphoma. The publication, entitled “Clinical Benefit Associated With Idiotypic Vaccination of Patients With Follicular Lymphoma” by Susana Inoges, et al (Journal of the National Cancer Institute, Vol. 98, No 18, 2006, pp1292-1301), was based on research conducted at the Oncology Division of the University of Navara, in Pamploma, Spain.
